These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 39046464)

  • 21. Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.
    Park SH; Belcastro E; Hasan H; Matsushita K; Marchandot B; Abbas M; Toti F; Auger C; Jesel L; Ohlmann P; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2021 Mar; 20(1):65. PubMed ID: 33726768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
    Habibi J; Aroor AR; Sowers JR; Jia G; Hayden MR; Garro M; Barron B; Mayoux E; Rector RS; Whaley-Connell A; DeMarco VG
    Cardiovasc Diabetol; 2017 Jan; 16(1):9. PubMed ID: 28086951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na
    Uthman L; Li X; Baartscheer A; Schumacher CA; Baumgart P; Hermanides J; Preckel B; Hollmann MW; Coronel R; Zuurbier CJ; Weber NC
    Biomed Pharmacother; 2022 Feb; 146():112515. PubMed ID: 34896968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence.
    Bayes-Genis A; Iborra-Egea O; Spitaleri G; Domingo M; Revuelta-López E; Codina P; Cediel G; Santiago-Vacas E; Cserkóová A; Pascual-Figal D; Núñez J; Lupón J
    Sci Rep; 2021 Jun; 11(1):12025. PubMed ID: 34103605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
    Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
    Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A role for tubular Na
    Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empagliflozin improves left ventricular diastolic function of db/db mice.
    Moellmann J; Klinkhammer BM; Droste P; Kappel B; Haj-Yehia E; Maxeiner S; Artati A; Adamski J; Boor P; Schütt K; Lopaschuk GD; Verma S; Marx N; Lehrke M
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165807. PubMed ID: 32353614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
    Sabatino J; De Rosa S; Tammè L; Iaconetti C; Sorrentino S; Polimeni A; Mignogna C; Amorosi A; Spaccarotella C; Yasuda M; Indolfi C
    Cardiovasc Diabetol; 2020 May; 19(1):66. PubMed ID: 32414364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
    Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
    Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction.
    Kim I; Cho HJ; Lim S; Seok SH; Lee HY
    Exp Mol Med; 2023 Jun; 55(6):1174-1181. PubMed ID: 37258583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
    Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
    Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal upregulation of NCC counteracts empagliflozin-mediated NHE3 inhibition in normotensive but not in hypertensive male rat.
    Castro PC; Santos-Rios TM; Martins FL; Crajoinas RO; Caetano MV; Lessa LMA; Luchi WM; McCormick JA; Girardi ACC
    Am J Physiol Cell Physiol; 2024 Jun; 326(6):C1573-C1589. PubMed ID: 38557357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
    Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
    Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dapagliflozin prevents ERK activation and SGLT2-dependent endoglin upregulation in a mechanically provoked cardiac injury model.
    Yeh TC; Wu YC; Wong TY; Sun GC; Tseng CJ; Cheng PW
    Physiol Rep; 2024 Apr; 12(7):e15990. PubMed ID: 38575554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
    Olgar Y; Turan B
    Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
    Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
    J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Ameliorate Metabolic Disorder and Obesity Induced Cardiomyocyte Injury and Mitochondrial Remodeling.
    Jhuo SJ; Lin YH; Liu IH; Lin TH; Wu BN; Lee KT; Lai WT
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Empagliflozin decreases myocardial cytoplasmic Na
    Baartscheer A; Schumacher CA; Wüst RC; Fiolet JW; Stienen GJ; Coronel R; Zuurbier CJ
    Diabetologia; 2017 Mar; 60(3):568-573. PubMed ID: 27752710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.